Pfizer to Acquire Array Biopharma for ~$11.4B

Share this


Pfizer to Acquire Array Biopharma for ~$11.4B


  • Pfizer to acquire Array Biopharma in all-stock transaction for $48/share making the total deal value ~11. Table4B- with its expected completion in H2’19
  • The focus of the acquisition is to bolster Pfizer’s oncology portfolio with the addition of Array’s combined therapy of Braftovi (encorafenib) and Mektovi (binimetinib) indicated for the treatment of BRAFV600E or BRAFV600K mutant unresectable or metastatic melanoma
  • Braftovi and Mektovi are BRAF/MEK inhibitors- being evaluated in P-III BEACON study as a triple combination therapy (braftovi + mektovi + cetuximab) in patients with BRAF-mutant mCRC with its expected regulatory submission in the US in H2’19

Ref: Pfizer | Image: Leaderonomics

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions